Cisplatin-CBV with autologous bone marrow transplantation for relapsed hodgkin's disease

Jorge A. Spinolo, Sundar Jagannath, William Velásquez, Gary Spitzer, Fernando Cabanillas, Fredrick Hagemeister, Leonard J. Horwitz, Karel A. Dicke

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The use of high-dose cyclophosphamide, carmustine, and etoposide (CBV) with autologous bone marrow transplantation (ABMT) results in long-term disease-free survival of about 30% in patients with relapsed Hodgkin's disease. Laboratory and clinical data show that cisplatin is synergistic with etoposide and carmustine, with non-overlapping extramedullary toxicity. Twenty-one patients with relapsed Hodgkin's disease that had progressed after both MOPP-like and ABVD-like regimens were treated with CBV plus cisplatin (90 mg/m2) and ABMT. The CR rate was 55%; the three-year disease-free and overall survival were 29% and 38% respectively; these results are comparable to prior experience with CBV. Performance status was strongly correlated with achievement of CR, survival, and time to treatment failure. Nephrotoxicity was seen in 3 patients, and ototoxicity in 1 patient. Although cisplatin could be added to CBV with minimal additional toxicity, the results obtained in this small patient population were not better than those of the earlier regimen. A larger trial in patients not previously exposed to cisplatin may better define the role of its addition to CBV.

Original languageEnglish
Pages (from-to)71-77
Number of pages7
JournalLeukemia and Lymphoma
Issue number1-2
StatePublished - 1993
Externally publishedYes


  • Autologous bone marrow transplant
  • Cisplatinum/CBV
  • Relapsed Hodgkin's disease


Dive into the research topics of 'Cisplatin-CBV with autologous bone marrow transplantation for relapsed hodgkin's disease'. Together they form a unique fingerprint.

Cite this